An over-arching strategy to help strengthen the UK's life sciences sector after Brexit has been unveiled today,with pharma, biotech and medtech companies hoping the government will follow i
The government’s Accelerated Access Review (AAR) was supposed to herald a new age of innovation in the NHS, cutting drug development times and encouraging the use of novel medicines and tre
The government must draw up a pharma-friendly industrial strategy to ensure the industry remains in the UK after Brexit, influential figures have said, as uncertainties mount about a future
Last week saw the publication of the UK's Accelerated Access Review, containing proposals to cut four years from the drug development process – but AstraZeneca seems unconvinced that access
The government has published its long-awaited Accelerated Access Review, a report that aims to cut up to four years from the process that gets a drug from the lab to use on England's Nation
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas